Good evening. Here's what's moving in the world of medical cannabis today.

NORML seeks representation at DEA rescheduling hearing

The National Organisation for the Reform of Marijuana Laws (NORML) has formally requested a seat at the upcoming Drug Enforcement Administration (DEA) hearing on the proposed rescheduling of cannabis in the United States. In a public statement, NORML argued that the hearing record would be incomplete unless it includes the perspective of adult cannabis consumers — the constituency it has represented for more than fifty years.

The DEA is currently considering moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, a change that would acknowledge its accepted medical use and reduce federal restrictions on research and prescribing. NORML's petition underscores the ongoing tension between federal regulatory processes and the interests of patients and consumers who have long advocated for reform.

NORML calls for renewed supporter engagement amid policy battles

In a separate appeal published this week, NORML urged its supporters to maintain their financial and grassroots backing, stating that the current political moment is critical for cannabis policy reform. The organisation emphasised that its work is "not about protecting Wall Street weed profits" but rather "finishing the fight for justice, equity, and freedom."

The call comes as the US federal rescheduling process continues to move slowly, with multiple stakeholders — including industry groups, patient advocates, and prohibitionist organisations — jostling for influence over the final outcome. NORML's appeal reflects a broader concern among advocacy groups that public momentum may wane before meaningful federal policy change is achieved.

No major UK or European medical cannabis stories in today's headlines

Today's available news feed contained no significant developments from the UK or European medical cannabis sectors. The Guardian's featured podcast on red-light therapy devices, whilst touching on skin health and scientific investigation, does not relate to cannabis or cannabinoid medicine and has not been included in this briefing.

Readers are reminded that The Ganja Club continues to monitor UK clinics, the CQC, MHRA, and Home Office for policy and regulatory updates, as well as European developments in Germany and EU-level cannabinoid reform. We will report on any breaking stories as they emerge.